Autism 200 SeriesBiomedical TherapiesA Practical Approach<br />Gary Stobbe, MD<br />Clinical Assistant Professor<br />Univ...
What are Biomedical Therapies?<br />Can be defined as any agent or therapy that directly influences the body’s internal en...
Case Study<br />3 ½ yo male<br />Normal pregnancy and delivery<br />Normal motor milestones<br />“Picture perfect” baby<br...
Case Study (cont.)<br />At 18 months, no more words and not responding to his name<br />Told probably just “late talker” <...
Case Study (cont.)<br />36 months, diagnosed with autism<br />Enrolled in developmental preschool, ABA therapy, OT, speech...
Questions<br />What caused this (“if I could just figure it out”)?<br />He’s improving, but is it fast enough?<br />Am I d...
Fast Forward…<br />Age 7, 1st grade with 1:1 aide <br />Struggling with social skills<br />Impulsive behaviors difficult t...
Fast Forward (again)<br />Age 16, ritualistic behavior interfering with daily activities<br />Explosive behaviors which we...
Biomedical Therapies in Autism<br />10 Rules to Get You Started<br />
Rule #1Psychoeducational therapy is the foundation of treatment.<br />Biomedicals should never replace behavioral approach...
Rule #2No biomedical therapy has proven to be effective in treating “core features” of autism.<br />Minimal “class 1” evid...
Social Impairment<br />ASD – Core Features<br />ASD<br />Language/<br />Comm. Deficits<br />Repetitive Behaviors/ Restrict...
Rule #3Autism treatment is symptom-based. Stratify treatment options based on risk.<br />Classic decision making for sympt...
PDD (DSM-IV) = ASD“symptom/behaviorally based”<br />
ASD“causally based”<br />
Causes of ASD<br /><ul><li>85% idiopathic, more common HFA, 4:1 m/f
Symptomatic/cryptogenic more commonly associated with MR, 1:1 m/f ratio
Genetic (tuberous sclerosis, fragile X, Angelman’s, Down’s)
Structural (migration defects, Moebius)
Perinatal (anoxia, infectious)
Epileptic (infantile spasms, Landau-Kleffner)</li></li></ul><li>Common Co-morbid Symptom Clusters in ASD - Behavioral<br /...
Common Co-morbid Symptom Clusters in ASD - Medical<br />Sleep (initiating, night-time awakening)<br />GI (IBS, food sensit...
Rule #4Maximizing health goes a long way.<br />Don’t always assume aberrant behaviors are purely due to autism.<br />Follo...
Rule #5Don’t go out on a limb if making good progress.<br />The opposite is also true – a lack of expected progress throug...
Measuring Progress in ASD<br />Clinical Global Impression – Parent Rating<br />Accurate, although often won’t know why<br ...
Biomedical Therapies – Barriers to Clinical Research<br />Poorly understood mechanisms/etiology<br />Probable multiple cau...
Rule #6Implement new treatment in  “controlled” setting if possible.<br />Avoid starting or changing therapies simultaneou...
Rule #7Define your endpoints.<br />Likelihood of successful treatment will increase if goals of treatment are clearly defi...
Rule #8Use “on-off” protocol if benefit not clear.<br />Difficult to see subtle benefit when improving anyway.<br />Trial ...
Rule #9Combinations usually work better than pushing the dose of a single agent.<br />Pervasive nature of the disorder oft...
Rule #10A treatment that gives benefit today is not necessarily beneficial tomorrow.<br />Some treatments may be age-speci...
Biomedical Therapies<br />Dietary Modification<br />Supplements<br />Pharmacological – Medical<br />Pharmacological – Beha...
Biomedical Therapies – Dietary Modification<br />Gluten and casein free most common<br />Possible improvements in hyperact...
Biomedical Therapies – Dietary Modification (cont.)<br />Theories<br />“Opioid excess theory” related to undigested protei...
Biomedical Therapies – Supplements<br />“Nutritional”<br />Zinc/iron (common deficiencies)<br />Others (individually based...
Biomedical Therapies – Supplements (cont.)<br />Methylcobalamin/folinic acid<br />Cofactors in methylation/sulfation enzym...
Biomedical Therapies – Antifungal/bacterial/viral<br />Antifungal based on “gut dysbiosis” theory<br />? Antiinflammatory ...
Biomedical Therapies – Sleep Disorder<br />Most effective for sleep initiation<br />Melatonin<br />Clonidine<br />Trazadon...
Biomedical Therapies – GI Dysfunction<br />IBS symptoms common<br />24% of autistics with GI symptoms (Molloy, Autism, 200...
Biomedical Therapies – Pharmacological<br />Serotonin Transporter Inhibitors (SSRIs)<br />Stimulants/non-stimulant ADD med...
Biomedical Therapies – Pharmacological (cont.)<br />SSRIs<br />Supported by studies implicating 5-HT (PET, blood)<br />Sup...
Biomedical Therapies – Pharmacological (cont.)<br />Stimulant/non-stimulant ADD meds<br />Targets ADHD symptoms (attention...
Biomedical Therapies – Pharmacological (cont.)<br />Neuroleptics<br />Targets irritability, aggression, impulsivity, ritua...
Biomedical Therapies – Pharmacological (cont.)<br />Anti-convulsants<br />? Association with regression<br />Up to 46% wit...
Biomedical Therapies – Experimental <br />Goal to find treatments of “core” features (language, social) not just symptom m...
Biomedical Therapies – Experimental (cont.)<br />Chelation therapy<br />Based on mercury/toxic metal theory<br />Oral DMSA...
Upcoming SlideShare
Loading in …5
×

Biomedical Therapies

1,292 views

Published on

Dr. Gary Stobbe's Autism 200 Series lecture: Biomedical Therapies: A Practical Approach.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,292
On SlideShare
0
From Embeds
0
Number of Embeds
9
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Biomedical Therapies

  1. 1. Autism 200 SeriesBiomedical TherapiesA Practical Approach<br />Gary Stobbe, MD<br />Clinical Assistant Professor<br />University of Washington<br />Attending Neurologist<br />Seattle Children’s Autism Center<br />
  2. 2. What are Biomedical Therapies?<br />Can be defined as any agent or therapy that directly influences the body’s internal environment<br />Includes diet/nutrition, nutraceuticals, pharmaceuticals, etc.<br />Traditionally excludes “hands-on” therapies (ABA, speech, OT, vision, AIT, CST, neurofeedback, etc.)<br />
  3. 3. Case Study<br />3 ½ yo male<br />Normal pregnancy and delivery<br />Normal motor milestones<br />“Picture perfect” baby<br />At 16 months, says first word<br />Enjoys physical play, investigates environment<br />Likes to play by himself<br />
  4. 4. Case Study (cont.)<br />At 18 months, no more words and not responding to his name<br />Told probably just “late talker” <br />24 months, hearing test normal<br />30 months, hand flapping when excited<br />Speech therapy started; referred for evaluation to r/o autism<br />
  5. 5. Case Study (cont.)<br />36 months, diagnosed with autism<br />Enrolled in developmental preschool, ABA therapy, OT, speech therapy<br />Now echoes some words<br />Eye contact improved<br />Loose stools, poor attention, poor sleep<br />
  6. 6. Questions<br />What caused this (“if I could just figure it out”)?<br />He’s improving, but is it fast enough?<br />Am I doing everything I can?<br />Do I believe the stories and try unproven (and potentially risky) treatments?<br />What do I do first?<br />
  7. 7. Fast Forward…<br />Age 7, 1st grade with 1:1 aide <br />Struggling with social skills<br />Impulsive behaviors difficult to control, can be violent<br />Severe anxiety over “trivial” events<br />Unable to stay on complex tasks<br />Teachers suggesting medication trial<br />
  8. 8. Fast Forward (again)<br />Age 16, ritualistic behavior interfering with daily activities<br />Explosive behaviors which were gone have recurred <br />Becoming more isolated<br />Now what?<br />
  9. 9. Biomedical Therapies in Autism<br />10 Rules to Get You Started<br />
  10. 10. Rule #1Psychoeducational therapy is the foundation of treatment.<br />Biomedicals should never replace behavioral approaches.<br />Highly unlikely that any biomedical will have maximal effect without an appropriate psychoeducational program.<br />
  11. 11. Rule #2No biomedical therapy has proven to be effective in treating “core features” of autism.<br />Minimal “class 1” evidence exists for biomedical therapies in ASD.<br />
  12. 12. Social Impairment<br />ASD – Core Features<br />ASD<br />Language/<br />Comm. Deficits<br />Repetitive Behaviors/ Restricted Interests<br />
  13. 13. Rule #3Autism treatment is symptom-based. Stratify treatment options based on risk.<br />Classic decision making for symptom-based diagnosis.<br />Because treatments generally have little or no efficacy data, risk plays heavy role in decision-making.<br />
  14. 14. PDD (DSM-IV) = ASD“symptom/behaviorally based”<br />
  15. 15. ASD“causally based”<br />
  16. 16. Causes of ASD<br /><ul><li>85% idiopathic, more common HFA, 4:1 m/f
  17. 17. Symptomatic/cryptogenic more commonly associated with MR, 1:1 m/f ratio
  18. 18. Genetic (tuberous sclerosis, fragile X, Angelman’s, Down’s)
  19. 19. Structural (migration defects, Moebius)
  20. 20. Perinatal (anoxia, infectious)
  21. 21. Epileptic (infantile spasms, Landau-Kleffner)</li></li></ul><li>Common Co-morbid Symptom Clusters in ASD - Behavioral<br />Anxiety/OCD (rigidity, sensory sensitivity, transition difficulties, “desire for sameness”)<br />Attention deficit (focus, impulsivity, planning, organization)<br />Mood instability (rapid cycling, extreme behaviors, poor impulse control)<br />
  22. 22. Common Co-morbid Symptom Clusters in ASD - Medical<br />Sleep (initiating, night-time awakening)<br />GI (IBS, food sensitivities, inflammatory)<br />Esophagitis responsible for severe abarrent behaviors<br />Seizures<br />30-40% classic autism with seizures by teens<br />Epileptiform discharges associated with poor progress? (causal vs. epiphenomenon)<br />
  23. 23. Rule #4Maximizing health goes a long way.<br />Don’t always assume aberrant behaviors are purely due to autism.<br />Follows similar rule as other CNS conditions.<br />Physical exercise, sleep very important.<br />
  24. 24. Rule #5Don’t go out on a limb if making good progress.<br />The opposite is also true – a lack of expected progress through conventional treatments warrants consideration of biomedical therapies.<br />
  25. 25. Measuring Progress in ASD<br />Clinical Global Impression – Parent Rating<br />Accurate, although often won’t know why<br />Clinical Global Impression – Clinician Rating<br />Objective Measures<br />Difficult to obtain in clinical setting<br />
  26. 26. Biomedical Therapies – Barriers to Clinical Research<br />Poorly understood mechanisms/etiology<br />Probable multiple causes<br />Lack of biomarkers<br />Pediatric population<br />Poor funding<br />Minimal pharmaceutical industry support<br />
  27. 27. Rule #6Implement new treatment in “controlled” setting if possible.<br />Avoid starting or changing therapies simultaneously, including hands-on therapies and changes in schedule or routine.<br />
  28. 28. Rule #7Define your endpoints.<br />Likelihood of successful treatment will increase if goals of treatment are clearly defined.<br />Define duration of treatment and objective (target symptom).<br />
  29. 29. Rule #8Use “on-off” protocol if benefit not clear.<br />Difficult to see subtle benefit when improving anyway.<br />Trial of discontinuation to observe regression – suggest “on” phase of 1-3 months.<br />
  30. 30. Rule #9Combinations usually work better than pushing the dose of a single agent.<br />Pervasive nature of the disorder often requires addressing multiple neurotransmitter systems.<br />The population is sensitive. Start low and go slow.<br />Remember to identify your target.<br />
  31. 31. Rule #10A treatment that gives benefit today is not necessarily beneficial tomorrow.<br />Some treatments may be age-specific.<br />The reverse may also be true regarding treatment tolerability.<br />
  32. 32. Biomedical Therapies<br />Dietary Modification<br />Supplements<br />Pharmacological – Medical<br />Pharmacological – Behavioral<br />Experimental<br />
  33. 33. Biomedical Therapies – Dietary Modification<br />Gluten and casein free most common<br />Possible improvements in hyperactivity, sleep, GI, and core feature<br />Improve health vs. core feature?<br />Additional behavioral benefit<br />www.gfcfdiet.com<br />
  34. 34. Biomedical Therapies – Dietary Modification (cont.)<br />Theories<br />“Opioid excess theory” related to undigested proteins interfering with brain function<br />“Autoimmunity theory” related to immune response (IgG Abs) to specific undigested protiens<br />Both theories imply “leaky gut”<br />Improvement over time expected (healing vs. development)<br />
  35. 35. Biomedical Therapies – Supplements<br />“Nutritional”<br />Zinc/iron (common deficiencies)<br />Others (individually based on diet)<br />“Therapeutic”<br />Omega-3 EFAs (Amminger, Biol Psychiatry. 2007). Improved hyperactivity, ?anxiety.<br />High dose B6/magnesium (Mausain-Bosc, Magnes Res, 2006). Improved attention.<br />Dimethylglycine (Kern, J.Child Neurol., 2001)<br />
  36. 36. Biomedical Therapies – Supplements (cont.)<br />Methylcobalamin/folinic acid<br />Cofactors in methylation/sulfation enzyme pathways<br />Important for integrity of CNS, immune, GI (Moretti, Neurology, 2005)<br />Improved biomarkers in 20 autistic children (James, J. DAN! Meeting, Portland, 2003)<br />Clinically unproven<br />
  37. 37. Biomedical Therapies – Antifungal/bacterial/viral<br />Antifungal based on “gut dysbiosis” theory<br />? Antiinflammatory effect<br />2 small group studies of antibacterial therapy showing unsustained benefit<br />Antiviral based on “stealth virus” theory or latent GI viral infection (Wakefield, Lancet, 1998 – data later shown to be falsified)<br />
  38. 38. Biomedical Therapies – Sleep Disorder<br />Most effective for sleep initiation<br />Melatonin<br />Clonidine<br />Trazadone<br />Tricyclics<br />Gabapentin<br />Neuroleptics<br />Consider sleep study<br />
  39. 39. Biomedical Therapies – GI Dysfunction<br />IBS symptoms common<br />24% of autistics with GI symptoms (Molloy, Autism, 2003)<br />Consider GI study for unexplained severe behaviors<br />Prevacid trial (possible esophagitis)<br />
  40. 40. Biomedical Therapies – Pharmacological<br />Serotonin Transporter Inhibitors (SSRIs)<br />Stimulants/non-stimulant ADD meds<br />Neuroleptics<br />Anticonvulsants<br />Sympatholytics<br />Others<br />
  41. 41. Biomedical Therapies – Pharmacological (cont.)<br />SSRIs<br />Supported by studies implicating 5-HT (PET, blood)<br />Supported by open label studies (fluoxetine, sertraline, citalopram) and blinded study (fluvoxamine)<br />Targets anxiety, ritualistic/compulsive/repetitive behaviors, maladaptive behavior, aggression<br />
  42. 42. Biomedical Therapies – Pharmacological (cont.)<br />Stimulant/non-stimulant ADD meds<br />Targets ADHD symptoms (attention, hyperactivity)<br />Frequent paradoxical worsening<br />Good safety data<br />Stimulants (methylphenidate, lisdexamfetamine) <br />alpha-adrenergic agonists (guanfacine, clonidine)<br />Newer non-stimulants (atomoxetine, modafinil)<br />Consider amantadine as alternative<br />
  43. 43. Biomedical Therapies – Pharmacological (cont.)<br />Neuroleptics<br />Targets irritability, aggression, impulsivity, ritualistic behavior<br />Good class 1 evidence (risperidone, aripiprazole)<br />Higher risk profile (weight gain, ? Diabetes, movement disorders)<br />
  44. 44. Biomedical Therapies – Pharmacological (cont.)<br />Anti-convulsants<br />? Association with regression<br />Up to 46% with EEG epileptiform findings<br />Target mood stabilization, irritability, compulsions, agressiveness<br />? Language improvement (Stobbe, AES Meeting, 2006)<br />Better safety with newer agents (oxcarbazapine, lamotrigine)<br />
  45. 45. Biomedical Therapies – Experimental <br />Goal to find treatments of “core” features (language, social) not just symptom management<br />No good supportive data currently<br />
  46. 46. Biomedical Therapies – Experimental (cont.)<br />Chelation therapy<br />Based on mercury/toxic metal theory<br />Oral DMSA approved for acute mercury and lead toxicity<br />? risk<br />Newborn hair study (Holmes, 2003)<br />Urine DMSA challenge study (Bradstreet, 2003)<br />Urinary porphyrin study discredits theory (Woods JS, 2010) <br />
  47. 47. Biomedical Therapies – Experimental (cont.)<br />Acetylcholinesterase Inhibitors<br />FDA approved for Alzheimer’s<br />Targets system important for language/memory<br />Acetylcholine neurons diminished in path. Studies<br />Several positive open-label studies<br />Good safety data in adults <br />
  48. 48. Biomedical Therapies – Experimental (cont.)<br />Immunomodulatory therapy<br />Supported by studies of immune system irregularities<br />Increased 1st-degree relatives with auto-immune disorders<br />Regressive pattern<br />Small studies with prednisone, IVIg<br />
  49. 49. Biomedical Therapies – Experimental (cont.)<br />Hyperbaric Oxygen Therapy (HBOT)<br />Based on oxidative stress theory<br />Two studies presented, conflicting data<br />Needs more research<br />Stem cell research (Duke University)<br />Oxytocin (Hollander E, 2008)<br />Transmagnetic Stimulation (TMS)<br />Neurofeedback Therapy<br />Naltrexone <br />Secretin<br />Center for Neurological Health (Bastyr U.)<br />
  50. 50. Thanks!<br />Contact Us<br />Seattle Children’s Autism Center<br />206-987-8080<br />www.seattlechildrens.org<br />

×